Business

Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis – Slideshow

Published

2 hours ago

on

31 August 2026

By

NewsAdmin

Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis – Slideshow

Related Topics:

You must be logged in to post a comment Login

Leave a Reply
Cancel reply

You must be logged in to post a comment.

Crypto World5 days ago

SpaceX stock could rise 75% to $240, JPMorgan says
Fashion2 days ago

Weekend Open Thread: Maeve – Corporette.com
Crypto World3 days ago

Bitcoin’s 22% rally now needs real demand to outlast Treasury liquidity boost
Crypto World4 days ago

Warsh Jackson Hole keynote puts financial innovation first
Crypto World6 days ago

A $30 Billion AI Fund Implodes, Now the SEC Is Investigating Wall Street’s Role
Business3 days ago

Salesforce Stock Soars 19% as Blowout Earnings and Agentforce AI Growth Silence Software Skeptics

Exit mobile version